AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences.
| Event: | Morgan Stanley - 21stAnnual Global Healthcare Conference |
| Format: | Fireside chat with Remi Barbier, President & CEO |
| Date: | Monday, September 11, 2023 |
| Where: | New York City |
| Event: | H.C. Wainwright - 25thAnnual Global Investment Conference |
| Format: | Corporate presentation by Eric Schoen, Chief Financial Officer |
| Date: | Monday, September 11, 2023 |
| Where: | New York City |
| Event: | JonesTrading - 2023 Healthcare Summit |
| Format: | Fireside chat with Remi Barbier, President & CEO |
| Date: | Tuesday, October 10th, 2023 |
| Where: | Miami |
| Event: | Jefferies - Inaugural Biotech CNS/Neuro Summit |
| Format: | Fireside chat with management |
| Date: | Wednesday, October 11, 2023 |
| Where: | New York City |
A webcast or subsequent archived replay of Cassava Sciences’ participation in these events may be available, depending on the conference and other factors. If a webcast or replay becomes available, it may be accessed via the Investors section of Cassava Sciences’ website at: www.CassavaSciences.com.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain. Our product candidates have not been approved by any regulatory authority, and their safety, efficacy or other desirable attributes have not been established.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.85 |
| Daily Change: | 0.03 0.88 |
| Daily Volume: | 1,564,152 |
| Market Cap: | US$137.110M |
November 25, 2024 November 07, 2024 September 24, 2024 September 09, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
